In the article, "Doxorubicin-loaded Drug-eluting beads Versus Conventional Transarterial Chemoembolization for Nonresectable Hepatocellular Carcinoma", which appeared in the pages 175-180, Issue 3, Vol. 21 of The Saudi Journal of Gastroenterology,\[[@ref1]\] in the Abstract section, the percentages "17%" and "28%" in the sentence "*Complete response (CR), objective response (OR), disease control (DC), and progressive disease (PD) rates were 11%, 24%, 17%, and 47%, respectively, in the DEB = TACE group compared with 4%, 32%, 28%, and 36%, respectively, in the c-TACE group*." should be written as "53%" and "64%" respectively.

In the Patients and Methods section, the word "non-HCC" in the first sentence "*This study retrospectively compares the efficacy and safety profile of DEB-TACE with that of C-TACE in the management of non-HCC*." should be written as "nonresectable HCC".

In the Patients and Methods section, the words "pre- and postclinical" in the third sentence "*All patients had pre- and postclinical and laboratory evaluation as well as cross-sectional imaging with triphasic computed tomography (CT) or magnetic resonance (MR) of the liver prior to and following the procedure to assess for tumor response*." should be replaced with the word "clinical".

These have now been corrected and reposted online.
